Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.

PURPOSE The purpose of this research was to test the therapeutic efficacy of an anthracycline-antibody conjugate for the treatment of human B-cell lymphoma in a preclinical animal model. EXPERIMENTAL DESIGN Doxorubicin (dox) conjugates of the murine and humanized versions of the anti B-cell antibody LL1, targeting CD74, were prepared, along with a nonspecific control dox-antibody conjugate, targeting carcinoembryonic antigen. Antibody conjugates carried approximately 8-10 drug molecules attached site-specifically at thiols of reduced interchain disulfide bonds. Conjugates were tested, initially in vitro, and then for therapeutic efficacy in a systemic model, using a lethal i.v. dose of Raji cells in SCID mice. RESULTS Dox-LL1 conjugates were shown to be stable and 3-fold more effective in vitro against the human B-cell Burkitt's lymphoma line, Raji, compared with the nonspecific control conjugate that did not target CD74 or B cells. When SCID mice were given an i.v. dose of 2.5 million Raji cells, they would die of disseminated disease within 15-25 days postinjection. A single dose of dox-LL1 conjugate, 117-350 micro g, given 5 days to 14 (advanced disease) days after injection of the Raji cells resulted in cure of most animals out to 180 days after injection of the cells, whereas animals in treatment control groups were not cured. The dose of dox-LL1 found useful in this work corresponds with a significantly lower drug dose than reported previously with other drug-antibody conjugates CONCLUSION CD74 appears to be a uniquely useful target antigen for delivery of drugs, effecting cures of animals with single, low doses of conjugate.

[1]  M. Brechbiel,et al.  Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Irwin Hollander,et al.  Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.

[3]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[4]  F. Marshall,et al.  Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. , 2001, The American journal of pathology.

[5]  S. Natsugoe,et al.  Invariant chain expression in gastric cancer. , 2001, Cancer letters.

[6]  P. Trail,et al.  Monoclonal antibody drug immunoconjugates for targeted treatment of cancer , 2003, Cancer Immunology, Immunotherapy.

[7]  J. Uhr,et al.  Disseminated or localized growth of a human B‐cell tumor (Daudi) in scid mice , 1990, International journal of cancer.

[8]  G. Capranico,et al.  Anthracyclines: selected new developments. , 2001, Current medicinal chemistry. Anti-cancer agents.

[9]  P. Trail,et al.  (6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin. , 1993, Bioconjugate chemistry.

[10]  P. Cresswell,et al.  Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[12]  J. Uhr,et al.  The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. , 1992, Blood.

[13]  K. Gelmon,et al.  Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of Clinical Oncology.

[14]  M. Juweid,et al.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.

[15]  G. Griffiths,et al.  Cytotoxicity with Auger electron‐emitting radionuclides delivered by antibodies , 1999, International journal of cancer.

[16]  M. Juweid,et al.  Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. , 1995, Cancer research.

[17]  P. A. Peterson,et al.  Intracellular transport of class II MHC molecules directed by invariant chain , 1990, Nature.

[18]  Goldenberg,et al.  Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines , 1999, Immunology.

[19]  Moldenhauer,et al.  Surface‐expressed invariant chain (CD74) is required for internalization of human leucocyte antigen‐DR molecules to early endosomal compartments , 1999, Immunology.

[20]  S. Briggs,et al.  New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. , 1989, Journal of medicinal chemistry.

[21]  M. Berger,et al.  Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse , 2002, Investigational New Drugs.

[22]  P. van Endert,et al.  Human major histocompatibility complex class II invariant chain is expressed on the cell surface. , 1990, The Journal of biological chemistry.

[23]  G. Yarranton,et al.  CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. , 2002, Cancer research.

[24]  W. Priebe.  Anthracycline antibiotics : new analogues, methods of delivery, and mechanisms of action , 1994 .

[25]  N. Kedersha,et al.  Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Cresswell,et al.  Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding , 1990, Nature.

[27]  D. Goldenberg,et al.  Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice , 2000, Cancer Immunology, Immunotherapy.

[28]  D. Newton,et al.  Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. , 2001, Blood.

[29]  A. Schally,et al.  Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. , 2002, International journal of oncology.

[30]  G. Griffiths,et al.  Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. , 1996, The Biochemical journal.

[31]  C. Rabourdin-Combe,et al.  The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. , 1996, Critical reviews in immunology.

[32]  M. Zacheis,et al.  Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. , 1995, Journal of immunology.

[33]  D. Goldenberg,et al.  Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. , 1989, Cancer research.